参考文献
1.Adamkiewicz TV，Abboud MR，Paley C，et al.Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.Blood，2009，114：4632-4638.
2.Agarwal MB，Gupte SS，Viswanathan C，et al.Long-term assessment of efficacy and safety of L1，an oral iron chelator，in transfusion dependent thalassaemia：Indian trial.Br J Haematol，1992，82：460-466.
3.Al-Refaie FN，Wonke B，Hoffbrand AV，et al.Efficacy and possible adverse effects of the oral iron chelator 1，2-dimethyl-3-hydroxypyridin-4-one（L1）in thalassemia major.Blood，1992，80：593-599.
4.Al-Refaie FN，Wonke B，Wickens DG，et al.Zinc concentration in patients with iron overload receiving oral iron chelator 1，2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.J Clin Pathol，1994，47：657-660.
5.Aldouri MA，Hoffbrand AV，Flynn DM，et al.High incidence of cardiomyopathy in betathalassemia patients receiving transfusion and iron chelation：reversal by intensified chelation.Acta Haematologica，1990，84：113-117.
6.Anastasi S，Lisi R，Abbate G，et al.Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient.Pediatr Endocrinol Rev，2011，8（Suppl 2）：345-347.
7.Anderson LJ，Holden S，Davis B，et al.Cardiovascular T2-star（T2*）magnetic resonance for the early diagnosis of myocardial iron overload.Eur Heart J，2001，22：2171-2179.
8.Anderson LJ，Westwood MA，Holden S，et al.Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine：a prospective study using T2* cardiovascular magnetic resonance.Br J Haematol，2004，127：348-355.
9.Ang AL，Shah F，Davis B，et al.Deferiprone Is Associated with Lower Serum Ferritin（SF）Relative to Liver Iron Concentration（LIC）Than Deferoxamine and Deferasirox-Implications for Clinical Practice（abstract）.Blood，2010，116：4246.
10.Angelucci E，Brittenham GM，McLaren CE，et al.Hepatic iron concentration and total body iron stores in thalassemia major.N Engl J Med，2000，343：327-331.
11.Angelucci E，Giovagnoni A，Valeri G，et al.Limitations of magnetic resonance imaging in measurement of hepatic iron.Blood，1997，90：4736-4742.
12.Au WY，Lam WW，Chu WW，et al.A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong.Haematologica，2008，93：784-786.
13.Aydinok Y，Kattamis A，Cappellini MD，et al.Deferasirox– Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload（HYPERION）（abstract）.Blood，2013：2257.
14.Ayidinok Y，Kattamis A，Cappellini MD，et al.Deferasirox-Deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal after 24 months in patients with severe transfusional iron overload（HYPERION）（abstract）.Haematologica，2014，99：229.
15.Aydinok Y，Evans P，Manz CY，et al.Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.Haematologica，2012a，97：835-841.
16.Aydinok Y，Ulger Z，Nart D，et al.A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferipronemonotherapy in patients with thalassemia major.Haematologica，2007，92：1599-1606.
17.Aydinok Y，Unal S，Oymak Y，et al.Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naive children with transfusional iron overload.Eur J Haematol，2012b，88：431-438.
18.Bauters T，Mondelaers V，Robays H，et al.Gastric ulcer in a child treated with deferasirox.Pharm World Sci，2010，32：112-113.
19.Blake DR，Winyard P，Lunec J，et al.Cerebral and ocular toxicity induced by desferrioxamine.Quarterly Journal of Medicine，1985，56：345-355.
20.Bloomfield SE，Markenson AL，Miller DR，et al.Lens opacities in thalassemia.J Pediatr Ophthalmol Strabismus，1978，15：154-156.
21.Borgna-Pignatti C，Cappellini MD，De Stefano P，et al.Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.Blood，2006，107：3733-3737.
22.Borgna-Pignatti C，Rugolotto S，De Stefano P，et al.Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.Haematologica，2004，89：1187-1193.
23.Bosquet J，Navarro M，Robert G，et al.Rapid desensitisation for desferrioxamine anaphylactoid reaction.Lancet，1983，2：859-860.
24.Brittenham GM，Cohen AR，McLaren CE，et al.Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.Am J Hematol，1993，42：81-85.
25.Brittenham GM，Griffith PM，Nienhuis AW，et al.Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major [see comments].N Engl J Med，1994，331：567-573.
26.Bronspiegel-Weintrob N，Olivieri NF，Tyler B，et al.Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.N Engl J Med，1990，323：713-719.
27.Buja LM，Roberts WC.Iron in the heart.Etiology and clinical significance.Am J Med，1971，51：209-221.
28.Cabantchik ZI，Breuer W，Zanninelli G，et al.LPI-labile plasma iron in iron overload.Best Pract Res Clin Haematol，2005，18：277-287.
29.Cappellini MD，Bejaoui M，Agaoglu L，et al.Iron chelation with deferasirox in adult and pediatric patients with thalassemia major：efficacy and safety during 5 years’ follow-up.Blood，2011，118：884-893.
30.Cappellini MD，Bejaoui M，Agaoglu L，et al.Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.Clin Ther，2007，29：909-917.
31.Cappellini MD，Cohen A，Piga A，et al.A phase 3 study of deferasirox（ICL670），a oncedaily oral iron chelator，in patients with beta-thalassemia.Blood，2006，107：3455-3462.
32.Cappellini MD，Porter J，El-Beshlawy A，et al.Tailoring iron chelation by iron intake and serum ferritin：the prospective EPIC study of deferasirox in 1744 patients with transfusiondependent anemias.Haematologica，2010，95：557-566.
33.Carpenter JP，He T，Kirk P，et al.On T2* magnetic resonance and cardiac iron.Circulation，2011，123：1519-1528.
34.Ceci A，Baiardi P，Felisi M，et al.The safety and effectiveness of deferiprone in a largescale，3-year study in Italian patients.British journal of haematology，2002，118：330-336.
35.Chao YH，Wu KH，Lin CY，et al.Audiologic and vestibular assessment in patients with beta-thalassemia major receiving long-term transfusion therapy.Pediatr Blood Cancer，2013，60：1963-1966.
36.Chatterjee R，Katz M，Oatridge A，et al.Selective loss of anterior pituitary volume with severe pituitary- gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest.Ann N Y Acad Sci，1998，850：479-482.
37.Chiodo AA，Alberti PW，Sher GD，et al.Desferrioxamine ototoxicity in an adult transfusion-dependent population.J Otolaryngol，1997，26：116-122.
38.Choudhry VP，Pati HP，Saxena A，et al.Deferiprone，efficacy and safety.Indian J Pediatr，2004，71：213-216.
39.Cohen AR，Galanello R，Piga A，et al.Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.Blood，2003，102：1583-1587.
40.Cohen AR，Galanello R，Piga A，et al.Safety profile of the oral iron chelator deferiprone：a multicentre study.Br J Haematol，2000，108：305-312.
41.Cohen AR，Glimm E，Porter JB.Effect of transfusional iron intake on response to chelation therapy in betathalassemia major.Blood，2008，111：583-587.
42.Cohen AR，Mizanin J，Schwartz E.Rapid removal of excessive iron with daily，high-dose intravenous chelation therapy.J Pediatr，1989，115：151-155.
43.Daar S，Pathare A，Nick H，et al.Reduction in labile plasma iron during treatment with deferasirox，a once-daily oral iron chelator，in heavily iron-overloaded patients with betathalassaemia.Eur J Haematol，2009，82：454-457.
44.Davies SC，Marcus RE，Hungerford JL，et al.Ocular toxicity of high-dose intravenous desferrioxamine.Lancet，1983，2：181-184.
45.Davis B，O’Sullivan C，Porter J.Value of LVEF monitoring in the long-term management of betathalassaemia.8th International Conference on Thalassemia and the hemoglobinopathies（Athens）2001；Abstract 056：147.
46.Davis BA，O’Sullivan C，Jarritt PH，et al.Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major.Blood，2004，104：263-269.
47.Davis BA，Porter JB.Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.Blood，2000，95：1229-1236.
48.De Virgillis S，Congia M，Frau F，et al.Desferrioxamineinduced growth retardation in patients with thalassaemia major.Journal of Pediatrics，1988，113：661-669.
49.Del Vecchio GC，Schettini F，Piacente L，et al.Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.Acta Haematol，2002，108：144-149.
50.Deugnier Y，Turlin B，Ropert M，et al.Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years.Gastroenterology，2011，141：1202-11，11 e1-e3.
51.Economou M，Printza N，Teli A，et al.Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.Acta haematologica，2010，123：148-152.
52.El-Beshlawy A，Manz C，Naja M，et al.Iron chelation in thalassemia：combined or monotherapy? The Egyptian experience.Ann Hematol，2008，87：545-550.
53.Elalfy M，Wali Y，Tony S，et al.Comparison Of Two Combination Iron Chelation Regimens，Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine，In Pediatric Patients With β-Thalassemia Major（abstract）.Blood，2013，22：559.
54.ElAlfy MS，Sari TT，Lee CL，et al.The safety，tolerability，and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.J Pediatr Hematol Oncol，2010，32：601-605.
55.Evans P，Kayyali R，Hider RC，et al.Mechanisms for the shuttling of plasma non-transferrinbound iron（NTBI）onto deferoxamine by deferiprone.Transl Res，2010，156：55-67.
56.Farmaki K，Tzoumari I，Pappa C，et al.Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.Br J Haematol，2010，148：466-475.
57.FDA drug prescribing information for ferriprox 2011.Available online at：www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf 2011.
58.Filosa A，Vitrano A，Rigano P，et al.Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.Blood Cells Mol Dis，2013，51：85-88.
59.Fischer R，Longo F，Nielsen P，et al.Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major：application of SQUID biomagnetic liver susceptometry.Br J Haematol，2003，121：938-948.
60.Fischer R，Piga A，De Sanctis V，et al.Large-Scale Study in Thalassemia Using Biomagnetic Liver Susceptometry.Biomag 98：Proc.11thInte.Conf.Biomagnetism（Sendai），1998：1-4.
61.Fisher CA，Premawardhena A，de Silva S，et al.The molecular basis for the thalassaemias in Sri Lanka.British journal of haematology，2003，121：662-671.
62.Fisher SA，Brunskill SJ，Doree C，et al.Oral deferiprone for iron chelation in people with thalassaemia.Cochrane Database Syst Rev，2013a；8：CD004839.
63.Fisher SA，Brunskill SJ，Doree C，et al.Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.Cochrane Database Syst Rev 2013b；8：CD004450.
64.Ford J，Rojkjaer L.Comment to：Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox.Haematologica，2008，2008；93：e49.
65.Freeman AP，Giles RW，Berdoukas VA，et al.Early left ventricular dysfunction and chelation therapy in thalassemia major.Ann Intern Med，1983，99：450-454.
66.Gabutti V，Piga A.Results of long-term iron-chelating therapy.Acta Haematol，1996，95：26-36.
67.Galanello R，Kattamis A，Piga A，et al.A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.Haematologica，2006，91：1241-1243.
68.Galanello R，Piga A，Alberti D，et al.Safety，tolerability，and pharmacokinetics of ICL670，a new orally active ironchelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.J Clin Pharmacol，2003，43：565-572.
69.Galanello R，Piga A，Cappellini MD，et al.Effect of food，type of food，and time of food intake on deferasirox bioavailability：recommendations for an optimal deferasirox administration regimen.J Clin Pharmacol，2008，48：428-435.
70.Garbowski M，Carpenter JP，Smith G，et al.Calibration of Improved T2* Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload（abstract）.Blood，2009，114：2004.
71.Goldberg SL，Giardina PJ，Chirnomas D，et al.The palatability and tolerability of deferasirox taken with different beverages or foods.Pediatr Blood Cancer，2013，60：1507-1512.
72.Gomber S，Saxena R，Madan N.Comparative efficacy of desferrioxamine，deferiprone and in combination on iron chelation in thalassemic children.Indian Pediatr，2004，41：21-27.
73.Gosriwatana I，Loreal O，Lu S，et al.Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.Anal Biochem，1999，273：212-220.
74.Grange S，Bertrand DM，Guerrot D，et al.Acute renal failure and Fanconi syndrome due to deferasirox.Nephrol Dial Transplant，2010，25：2376-2378.
75.Gutiérrez Macías A，Lizarralde Palacios E，Olabarría Santurtún I，et al.Sindrome de hipers ensibilidadretardadainducido por deferasirox [Deferasirox-induced delayed hypersensitivity syndrome].Med Clin（Barc），2010，134：329-330.
76.Ha SY，Chik KW，Ling SC，et al.A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.Hemoglobin，2006，30：263-274.
77.Hod EA，Zhang N，Sokol SA，et al.Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation.Blood，2010，115：4284-4292.
78.Hoffbrand AV，F AL-R，Davis B，et al.Long-term trial of deferiprone in 51 transfusiondependent iron overloaded patients.Blood，1998，91：295-300.
79.Jensen PD，Jensen FT，Christensen T，et al.Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine：indication of close relation between myocardial iron content and chelatable iron pool.Blood，2003，101：4632-4639.
80.Jensen PD，Jensen FT，Christensen T，et al.Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging.Br J Haematol，1994，87：171-184.
81.Kattamis A，Ladis V，Berdousi H，et al.Iron chelation treatment with combined therapy with deferiprone and deferioxamine：a 12-month trial.Blood Cells Mol Dis，2006，36：21-25.
82.Kirk P，He T，Anderson LJ，et al.International reproducibility of single breathhold T2*MR for cardiac and liver iron assessment among five thalassemia centers.J MagnReson Imaging，2010，32：315-319.
83.Kirk P，Roughton M，Porter JB，et al.Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.J.of Cardiovasr Mag Res，2009a，1（Suppl 1）：O2：1-2.
84.Kirk P，Roughton M，Porter JB，et al.Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.Circulation，2009b，120：1961-1968.
85.Kontoghiorghes GJ，Goddard JG，Bartlett AN，et al.Pharmacokinetic studies in humans with the oral iron chelator 1，2-dimethyl-3-hydroxypyrid-4-one.Clinical Pharmacology，1990，48：255-261.
86.Lal A，Porter J，Sweeters N，et al.Combined chelation therapy with deferasiroxand deferoxamine in thalassemia.Bld cells，molecules & diseases，2013，50：99-104.
87.Limenta LM，Jirasomprasert T，Jittangprasert P，et al.Pharmacokinetics of deferiprone in patients with betathalassaemia：impact of splenectomy and iron status.Clin Pharmacokinet，2011，50：41-50.
88.Maclean KH，Cleveland JL，Porter JB.Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.Blood，2001，98：3831-3839.
89.Maggio A，D’Amico G，Morabito A，et al.Deferiprone versus deferoxamine in patients with thalassemia major：a randomized clinical trial.Blood Cells Mol Dis，2002，28：196-208.
90.Maggio A，Filosa A，Vitrano A，et al.Iron chelation therapy in thalassemia major：A systematic review with meta-analyses of 1520 patients included on randomized clinical trials.Bld cells，molecules & diseases，2011，47：166-175.
91.Maggio A，Vitrano A，Capra M，et al.Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients：a randomized clinical trial.British Journal of Haematology，2009，145：245-254.
92.Maggio A，Vitrano A，Lucania G，et al.Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.American journal of hematology，2012，87：732-733.
93.Marcus RE，Davies SC，Bantock HM，et al.Desferrioxamine to improve cardiac function in iron overloaded patients with thalassaemia major.Lancet，1984，1：392-393.
94.Miller JM，Horger EO，Key TC，et al.Management of sickle hemoglobinopathies in pregnant patients.Obstetrics & Gynecology，1981，141：237-241.
95.Modell B，Khan M，Darlison M.Survival in betathalassaemia major in the UK：data from the UK Thalassaemia Register.Lancet，2000，355：2051-2052.
96.Mourad FH，Hoffbrand AV，Sheikh-Taha M，et al.Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.Br J Haematol，2003，121：187-189.
97.Nisbet-Brown E，Olivieri NF，Giardina PJ，et al.Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia：a randomised，double-blind，placebo-controlled，dose-escalation trial.Lancet，2003，361：1597-1602.
98.Noetzli LJ，Carson SM，Nord AS，et al.Longitudinal analysis of heart and liver iron in thalassemia major.Blood，2008，112：2973-2978.
99.Noetzli LJ，Papudesi J，Coates TD，et al.Pancreatic iron loading predicts cardiac iron loading in thalassemia major.Blood，2009，114：4021-4026.
100.Novartis 2013.Summary of Product Characteristics.Available online at：http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/ human/000670/WC500033925.pdf.2013.
101.Olivieri N，Brittenham G.Final Results of the randomised trial of deferiprone and deferoxamine.Blood，1997，90：264a.
102.Olivieri NF，Brittenham GM，Matsui D，et al.Iron-chelation therapy with oral deferiprone in patients with thalassemia major [see comments].N Engl J Med，1995，332：918-922.
103.Olivieri NF，Brittenham GM，McLaren CE，et al.Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.The New England journal of medicine，1998a，339：417-423.
104.Olivieri NF，Buncic JR，Chew E，et al.Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.N Engl J Med，1986，314：869-873.
105.Olivieri NF，Koren G，Harris J，et al.Growth failure and bony changes induced by deferoxamine.American Journal of Pediatric Hematology Oncology，1992，14：48-56.
106.Olivieri NF，Nathan DG，MacMillan JH，et al.Survival in medically treated patients with homozygous betathalassemia.New England Journal of Medicine，1994，331：574-578.
107.Origa R，Bina P，Agus A，et al.Combined therapy with deferiprone and desferrioxamine in thalassemia major.Haematologica，2005，90：1309-1314.
108.Otto-Duessel M，Aguilar M，Nick H，et al.Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.Exp Hematol，2007，35：1069-1073.
109.Pennell D.MRI and iron-overload cardiomyopathy in thalassaemia.Circulation，2006a，113：f43-f44.
110.Pennell DJ，Berdoukas V，Karagiorga M，et al.Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis.Blood，2006b，107：3738-3744.
111.Pennell DJ，Porter JB，Cappellini MD，et al.Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major.Haematologica，2012，97：842-848.
112.Pennell DJ，Porter JB，Cappellini MD，et al.Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.Blood，2010，115：2364-2371.
113.Pennell DJ，Porter JB，Piga A，et al.A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major（CORDELIA）.Blood，2014，123：1447-1454.
114.Pepe A，Meloni A，Capra M，et al.Deferasirox，deferiprone and desferrioxamine treatment in thalassemia major patients：cardiac iron and function comparison determined by quantitative magnetic resonance imaging.Haematologica，2011，96：41-47.
115.Pepe A，Meloni A，Rossi G，et al.Cardiac and hepatic iron and ejection fraction in thalassemia major：multicentre prospective comparison of combined deferiproneand deferoxamine therapy against deferiprone or deferoxamine monotherapy.Journal of cardiovascular magnetic resonance ：official journal of the Society for Cardiovascular Magnetic Resonance，2013，15：1.
116.Piga A，Galanello R，Forni GL，et al.Randomized phase II trial of deferasirox（Exjade，ICL670），a once-daily，orally-administered iron chelator，in comparison to deferoxamine in thalassemia patients with transfusional iron overload.Haematologica，2006，91：873-880.
117.Piga A，Longo F，Duca L，et al.High nontransferrin bound iron levels and heart disease in thalassemia major.Am J Hematol，2009，84：29-33.
118.Piga A，Luzzatto L，Capalbo P，et al.High dose desferrioxamine as a cause of growth failure in thalassaemic patients.European Journal Haematology，1988，40：380-381.
119.Pippard MJ，Callender ST，Finch CA.Ferrioxamine excretion in iron-loaded man.Blood，1982，60：288-294.
120.Pongtanakul B，Viprakasit V.Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.Blood Cells Mol Dis，2013，51：96-97.
121.Porter J，Bowden DK，Economou M，et al.Health-Related Quality of Life，Treatment Satisfaction，Adherence and Persistence in beta-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox：Results from the EPIC Clinical Trial.Anemia，2012，2012：297641.
122.Porter J，Hershko C.The properties of Clinically useful Iron Chelators Iron Phyisology and Pathophysiology in Humans，Editors Anderson HJ and McLaren GD.Humana Press（Book），2012，Chapter 28：591-630.
123.Porter J，Galanello R，Saglio G，et al.Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox（ICL670）：a 1-yr prospective study.Eur J Haematol，2008，80：168-176.
124.Porter JB，Tanner MA，Pennell DJ，et al.Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670（Deferasirox）（abstract）.Blood，2005a，106：3600.
125.Porter JB，Abeysinghe RD，Marshall L，et al.Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.Blood，1996，88：705-713.
126.Porter JB，Davis BA.Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.Best Pract Res Clin Haematol，2002，15：329-368.
127.Porter JB，Elalfy MS，Taher AT，et al.Efficacy and safety of deferasirox at low and high iron burdens：results from the EPIC magnetic resonance imaging substudy.Annals of hematology，2013a，92：211-219.
128.Porter JB，Faherty A，Stallibrass L，et al.A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.Ann N Y Acad Sci，1998，850：483-487.
129.Porter JB，Jaswon MS，Huehns ER，et al.Desferrioxamine ototoxicity：evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.Br J Haematol，1989，73：403-409.
130.Porter JB，Lin KH，Beris P，et al.Response of iron overload to deferasirox in rare transfusion-dependent anaemias：equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Eur J Haematol，2011，87：338-348.
131.Porter JB，Rafique R，Srichairatanakool S，et al.Recent insights into interactions of deferoxamine with cellular and plasma iron pools：Implications for clinical use.Annals of the New York Academy of Sciences，2005b，1054：155-168.
132.Porter JB，Shah FT.Iron overload in thalassemia and related conditions：therapeutic goals and assessment of response to chelation therapies.Hematol Oncol Clin North Am，2010，24：1109-1130.
133.Porter JB，Wood J，Olivieri N，et al.Treatment of heart failure in adults with thalassemia major：response in patients randomised to deferoxamine with or without deferiprone.Journal of cardiovascular magnetic resonance ：official journal of the Society for Cardiovascular Magnetic Resonance，2013b，15：38.
134.Rheault MN，Bechtel H，Neglia JP，et al.Reversible Fanconi syndrome in a pediatric patient on deferasirox.Pediatr Blood Cancer，2011，56：674-676.
135.Sharma R，Anand R，Chandra J，et al.Distal ulnar changes in children with thalassemia and deferiprone related arthropathy.Pediatr Blood Cancer，2013.
136.Singh S，Hider RC，Porter JB.A direct method for quantification of non-transferrin-bound iron.Anal Biochem，1990，186：320-323.
137.St Pierre TG，Clark PR，Chua-anusorn W，et al.Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.Blood，2005，105：855-861.
138.Storey P，Thompson AA，Carqueville CL，et al.R2* imaging of transfusional iron burden at 3T and comparison with 1.5T.J MagnReson Imaging，2007，25：540-547.
139.Taher A，El-Beshlawy A，Elalfy MS，et al.Efficacy and safety of deferasirox，an oral iron chelator，in heavily iron-overloaded patients with beta-thalassaemia：the ESCALATOR study.Eur J Haematol，2009.
140.Taher AT，Porter JB，Viprakasit V，et al.Deferasirox effectively reduces iron overload in non-transfusiondependent thalassemia（NTDT）patients：1-year extension results from the THALASSA study.Annals of hematology，2013，92：1485-1493.
141.Tanner MA，Galanello R，Dessi C，et al.A randomized，placebo-controlled，double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.Circulation，2007，115：1876-1884.
142.Tanner MA，Galanello R，Dessi C，et al.Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.J CardiovascMagnReson，2006，8：543-547.
143.Telfer P.Update on survival in thalassemia major.Hemoglobin，2009，33（Suppl 1）：S76-S80.
144.Telfer P，Coen PG，Christou S，et al.Survival of medically treated thalassemia patients in Cyprus.Trends and risk factors over the period 1980-2004.Haematologica，2006，91：1187-1192.
145.Thomas A，Garbowski M，Ang A，et al.A Decade Followup of a Thalassemia Major（TM）Cohort Monitored by Cardiac Magnetic Resonance Imaging（CMR）：Significant Reduction In Patients with Cardiac Iron and In Total Mortality.Blood，2010，116：Abstract 1011.
146.Tondury P，Zimmermann A，Nielsen P，et al.Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.British Journal of Haematology，1998，101：413-415.
147.Traynor K.Deferiprone approved for iron overload.Am J Health Syst Pharm，2011，68：2106.
148.Tsou AY，Friedman LS，Wilson RB，et al.Pharmacotherapy for Friedreich ataxia.CNS Drugs，2009，23：213-223.
149.Vichinsky M，Bernaudin F，Forni GL，et al.Long-Term Safety and Efficacy of Deferasirox（Exjade®）In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years（abstract）.Blood，2010，116：845.
150.Vichinsky E.Clinical application of deferasirox：practical patient management.Am J Hematol，2008，83：398-402.
151.Villeneuve JP，Bilodeau M，Lepage R，et al.Variability in hepatic iron concentration measurement from needle- biopsy specimens.Journal of Hepatology，1996，25：172-177.
152.Viprakasit V，Ibrahim H，Ha SY，et al.Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific：a subanalysis of the EPIC study of deferasirox.Int J Hematol，2011，93：319-328.
153.Viprakasit V，Nuchprayoon I，Chuansumrit A，et al.Deferiprone［GPO-L-ONE（R）］monotherapy reduces iron overload in transfusion-dependent thalassemias：1-year results from a multicenter prospective，single arm，open label，dose escalating phase III pediatric study（GPO-L-ONE；A001）from Thailand.American journal of hematology，2013，88：251-260.
154.Vlachodimitropoulou E，Garbowski M，Porter JB.Modelling Combination Chelation Regimes to Optimize Cellular Iron Removal and explore mechanisms of enhanced chelation.Blood，2013，Abstract 2200.
155.Voskaridou E，Christoulas D，Terpos E.Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.British journal of haematology，2011，154：654-656.
156.Waldmeier F，Bruin GJ，Glaenzel U，et al.Pharmacokinetics，metabolism，and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.Drug Metab Dispos，2010，38：808-816.
157.Wanless IR，Sweeney G，Dhillon AP，et al.Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent betathalassemia.Blood，2002，100：1566-1569.
158.Wei HY，Yang CP，Cheng CH，et al.Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months.Transfusion，2011，51：949-954.
159.Wolfe L，Olivieri N，Sallan D，et al.Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.N Engl J Med，1985，312：1600-1603.
160.Wood JC.Diagnosis and management of transfusion iron overload：the role of imaging.Am J Hematol，2007，82：1132-1135.
161.Wood JC，Ghugre N.Magnetic resonance imaging assessment of excess iron in thalassemia，sickle cell disease and other iron overload diseases.Hemoglobin，2008，32：85-96.
162.Wood JC，Glynos T，Thompson A，et al.Relationship between labile plasma iron，liver iron concentration and cardiac response in a deferasiroxmonotherapy trial.Haematologica，2011，96：1055-1058.
163.Worwood M，Cragg SJ，Jacobs A，et al.Binding of serum ferritin to concanavalin A：patients with homozygous beta thalassaemia and transfusional iron overload.Br J Haematol，1980，46：409-416.
164.Yadav SK，Gupta V，El Kohly A，et al.Perforated duodenal ulcer：a rare complication of deferasirox in children.Indian J Pharmacol，2013，45：293-294.
165.Yarali N，Fisgin T，Duru F，et al.Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.J Pediatr Hematol Oncol，2006，28：11-16.
166.YesimAydinok P，Patricia Evans，Dr.2，AysenTerzi，PhD1，*et al.Randomised Prospective Evaluation of Iron Balance，Chelation Efficiency，Urine Excretion and NTBI Progression with Deferiprone（DFP）or Deferoxamine（DFO）Monotherapy or with Combined DFP Plus DFO（abstract）.Blood，2005，106：269.
167.Zanninelli G，Breuer W，Cabantchik ZI.Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.Br J Haematol，2009，147：744-751.